We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+3.75%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
(-4.1%)
Cap. Flow
-$282M
Cap. Flow
% of AUM
-9.39%
Top 10 Holdings %
Top 10 Hldgs %
30.38%
Holding
102
New
28
Increased
19
Reduced
31
Closed
14
Avg Time Held
3.5
quarters
Top 10 Avg Time Held
3.5
quarters
Top 20 Avg Time Held
3.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iRhythm Holdings
IRTC
|
+$56.7M |
| 2 |
Guardant Health
GH
|
+$50.2M |
| 3 |
Generate Biomedicines
GENB
|
+$43.9M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$43.2M |
| 5 |
argenx
ARGX
|
+$42.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$82.6M |
| 2 |
Align Technology
ALGN
|
+$59.5M |
| 3 |
CG Oncology
CGON
|
+$50.2M |
| 4 |
RAPT Therapeutics
RAPT
|
+$31.5M |
| 5 |
Legend Biotech
LEGN
|
+$28.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.27% |
| 2 | Miscellaneous | 12.42% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Bright Minds Biosciences
DRUG
$494M
| $39.4M | 1.31% |
539,708
+215,350
| +66% | +$17.3M |
2025 Q3
2 quarters
|
|
27
CareDx
CDNA
$3.39B
| $37.7M | 1.26% |
2,173,146
+587,926
| +37% | +$11.1M |
2025 Q3
2 quarters
|
|
28
Intuitive Surgical
ISRG
$147B
| $35.6M | 1.19% |
77,297
-6,120
| -7% | -$3.1M |
2024 Q1
8 quarters
|
|
29
Inspire Medical Systems
INSP
$1.96B
| $34.9M | 1.17% |
677,570
+136,680
| +25% | +$9.57M |
2023 Q3
10 quarters
|
|
30
Penumbra
PEN
$12.6B
| $34.6M | 1.15% |
105,352
-4,800
| -4% | -$1.63M |
2022 Q4
13 quarters
|
|
31
Transmedics
TMDX
$2.62B
| $32.7M | 1.09% |
329,391
+14,050
| +4% | +$1.83M |
2024 Q4
5 quarters
|
|
32
DELISTED
Soleno Therapeutics
SLNO
| $32.1M | 1.07% |
959,259
-228,600
| -19% | -$8.96M |
2025 Q3
2 quarters
|
|
33
Dyne Therapeutics
DYN
$2.76B
| $30.5M | 1.02% |
1,681,998
+203,669
| +14% | +$3.51M |
2024 Q4
5 quarters
|
|
34
Maravai LifeSciences
MRVI
$970M
| $29M | 0.97% |
10,240,164
+1,886,877
| +23% | +$6.4M |
2023 Q2
11 quarters
|
|
35
Illumina
ILMN
$40.6B
| $28.3M | 0.94% |
229,215
-40,458
| -15% | -$5.31M |
2025 Q4
1 quarter
|
|
36
Kymera Therapeutics
KYMR
$8.85B
| $28.1M | 0.94% |
337,559
-116,700
| -26% | -$9.24M |
2025 Q3
2 quarters
|
|
37
BioMarin Pharmaceuticals
BMRN
$10.7B
| $28.1M | 0.94% |
497,020
-104,500
| -17% | -$6.09M |
2025 Q3
2 quarters
|
|
38
Nurix Therapeutics
NRIX
$2.6B
| $27.1M | 0.91% |
1,750,766
-433,098
| -20% | -$7.18M |
2025 Q4
1 quarter
|
|
39
Rhythm Pharmaceuticals
RYTM
$6.01B
| $27M | 0.9% |
+310,628
| New | +$30.2M |
2026 Q1
0 quarters
|
|
40
Danaher
DHR
$157B
| $26.4M | 0.88% |
139,327
+21,100
| +18% | +$4.49M |
2025 Q1
4 quarters
|
|
41
Establishment Labs
ESTA
$1.72B
| $26.3M | 0.88% |
+463,600
| New | +$31.7M |
2026 Q1
0 quarters
|
|
42
Tectonic Therapeutic
TECX
$405M
| $26.2M | 0.87% |
847,151
-80,373
| -9% | -$1.98M |
2025 Q3
2 quarters
|
|
43
Natera
NTRA
$57.5B
| $25.8M | 0.86% |
129,000
+17,500
| +16% | +$3.77M |
2025 Q4
1 quarter
|
|
44
Corvus Pharmaceuticals
CRVS
$778M
| $25.6M | 0.86% |
+1,752,798
| New | +$28M |
2026 Q1
0 quarters
|
|
45
Fulcrum Therapeutics
FULC
$280M
| $24M | 0.8% |
3,134,922
+73,700
| +2% | +$684K |
2025 Q3
2 quarters
|
|
46
Zura Bio
ZURA
$421M
| $23.7M | 0.79% |
3,988,989
+808,600
| +25% | +$4.88M |
2024 Q3
6 quarters
|
|
47
Alphatec Holdings
ATEC
$1.6B
| $23.6M | 0.79% |
+2,172,725
| New | +$31.6M |
2026 Q1
0 quarters
|
|
|
DMRA
48
Damora Therapeutics
DMRA
$1.11B
| $23.2M | 0.77% |
+894,846
| New | +$23M |
2026 Q1
0 quarters
|
|
49
Boston Scientific
BSX
$61.7B
| $21.7M | 0.73% |
+346,467
| New | +$27.7M |
2026 Q1
0 quarters
|
|
50
Vera Therapeutics
VERA
$1.92B
| $21.1M | 0.7% |
523,824
-260,918
| -33% | -$11.2M |
2025 Q3
2 quarters
|
|
Similar funds
M
AG
NIM
GC
CCM
ACP
GBCP
SCM
Braidwell's Q1 2026 Portfolio in Review
As of Q1 2026, Braidwell held 102 positions worth $3B, down 4.1% from $3.13B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Braidwell withdrew a net $282M in Q1 2026, closing 14 positions and reducing 31 holdings. Its most notable exit was Align Technology, an estimated $59.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Guardant Health worth $46.2M.
- Braidwell's largest Q1 2026 buy was Guardant Health: 499,712 shares worth $46.2M.
- Braidwell added most to iRhythm Holdings in Q1 2026, an estimated $56.7M increase.
- Braidwell's biggest Q1 2026 reduction was Edgewise Therapeutics, cutting an estimated $82.6M.
- Braidwell fully exited Align Technology in Q1 2026, selling an estimated $59.5M.
- Braidwell's ten largest holdings make up 30% of its $3B portfolio in Q1 2026.
- Braidwell opened 28 new positions and closed 14 in Q1 2026.
- Braidwell's portfolio value fell 4.1% quarter-over-quarter to $3B.
Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.